AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4608503 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving SK)
Number of subjects: 2000
Study 30985244 — intervention group
Group type: EXPERIMENTAL
Intervention: PPIC 2.1 survey administered to beneficiaries
Number of subjects: 12364
Study 30985244 — intervention group
Group type: EXPERIMENTAL
Intervention: PPIC 2.1 survey
Number of subjects: 12364
Study 31052322 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull beverage (RB)
Number of subjects: 19
Study 31052322 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 19
Study 29717841 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple acupuncture at the Qugu acupoint (twice a week for 4 weeks)
Number of subjects: 90
Study 29717841 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin Mesylate Tablets (0.5 g, tid) + Terazosin Hydrochloride Capsules (2 mg qd) for 4 weeks
Number of subjects: 90
Study 25481694 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular endurance and resisted strengthening protocols
Number of subjects: 79
Study 25481694 — intervention group
Group type: COMPARATOR
Intervention: Routine activity maintenance (Control)
Number of subjects: 79
Study 24636286 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV
Number of subjects: 218
Study 24636286 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV maleate
Number of subjects: 218
Study 21682910 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-based intervention including telephone contacts, written information provision, home visitation, and contact with treating health professionals.
Number of subjects: 0
Study 21682910 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group).
Number of subjects: 0
Study 18413983 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous thromboembolism prophylaxis (mechanical, pharmacological, or a combination of both)
Number of subjects: 0
Study 16797994 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile bearing UKA (Oxford)
Number of subjects: 48
Study 16797994 — intervention group
Group type: COMPARATOR
Intervention: Fixed bearing UKA (Miller/Galante)
Number of subjects: 48
Study 16797994 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 15008339 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer (resin-modified glass ionomer)
Number of subjects: 12
Study 15008339 — intervention group
Group type: COMPARATOR
Intervention: Dyract (polyacid-modified resin)
Number of subjects: 12
Study 10753731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae
Number of subjects: 120
Study 10753731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9064671 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids supplementation
Number of subjects: 32
Study 9064671 — intervention group
Group type: COMPARATOR
Intervention: Control group (no n-3 fatty acids)
Number of subjects: 32
Study 1612952 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothalamic‐pituitary radiation therapy
Number of subjects: 47
Study 1612952 — intervention group
Group type: COMPARATOR
Intervention: Control (nonirradiated)
Number of subjects: 47
Study 1612952 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 47
Study 6145533 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol (1 mg/hr)
Number of subjects: 7
Study 6145533 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol (2 mg/hr)
Number of subjects: 7
Study 6145533 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (300 micrograms/hr)
Number of subjects: 7
Study 6145533 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (600 micrograms/hr)
Number of subjects: 7
Study 6145533 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (low dose)
Number of subjects: 7
Study 30678710 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient follow-up from the patient's home using telemedicine (teleSCI)
Number of subjects: 0
Study 30678710 — intervention group
Group type: COMPARATOR
Intervention: Usual care (hospital outpatient follow-up)
Number of subjects: 0
Study 30678710 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (teleSCI)
Number of subjects: 0
Study 29957706 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype 1 (lower plasma concentrations of TNF-α, IL-6, IL-8)
Number of subjects: 242
Study 29957706 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype 2 (higher plasma concentrations of TNF-α, IL-6, IL-8)
Number of subjects: 242
Study 29957706 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP in Phenotype 1
Number of subjects: 242
Study 29957706 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PEEP in Phenotype 1
Number of subjects: 242
Study 29957706 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP in Phenotype 2
Number of subjects: 242
Study 29957706 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PEEP in Phenotype 2
Number of subjects: 242
Study 27173380 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging diet (CD) with 10% proteins/45% lipids/45% carbohydrates (fat on sugar ratio = 1)
Number of subjects: 34
Study 27173380 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (BD) with 10% proteins/30% lipids/60% carbohydrates (fat on sugar ratio = 0.5)
Number of subjects: 34
Study 25375154 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 529
Study 25375154 — intervention group
Group type: COMPARATOR
Intervention: Non-users
Number of subjects: 529
Study 23147138 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of RIX4414 vaccine (n = 328)
Number of subjects: 653
Study 23147138 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 325)
Number of subjects: 653
Study 21056809 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 1 μg/mL
Number of subjects: 122
Study 21056809 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 2 μg/mL
Number of subjects: 122
Study 21056809 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 3 μg/mL
Number of subjects: 122
Study 21056809 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 4 μg/mL
Number of subjects: 122
Study 21056809 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 5 μg/mL
Number of subjects: 122
Study 21056809 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at 6 μg/mL
Number of subjects: 122
Study 21056809 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane alone
Number of subjects: 122
Study 17163285 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 50 mg
Number of subjects: 252
Study 17163285 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen 100 mg
Number of subjects: 252
Study 14570662 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl infusion (30 microg/h)
Number of subjects: 48
Study 14570662 — intervention group
Group type: COMPARATOR
Intervention: IV fentanyl infusion (30 microg/h)
Number of subjects: 48
Study 14570662 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl infusion
Number of subjects: 48
Study 11115439 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1N hydrochloric acid (HCl) perfusion
Number of subjects: 7
Study 11115439 — intervention group
Group type: COMPARATOR
Intervention: Saline solution perfusion
Number of subjects: 7
Study 9175684 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma interleukin-1 receptor antagonist (IL-1ra) levels in pre-eclampsia group
Number of subjects: 30
Study 9175684 — intervention group
Group type: COMPARATOR
Intervention: Plasma interleukin-1 receptor antagonist (IL-1ra) levels in uncomplicated pregnancy group
Number of subjects: 30
Study 9175684 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1ra predictive values at gestational weeks 20-25
Number of subjects: 30
Study 1564652 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M multifocal IOL
Number of subjects: 77
Study 1564652 — intervention group
Group type: COMPARATOR
Intervention: Conventional monofocal implant
Number of subjects: 77
Study 3890786 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy alone (32 patients)
Number of subjects: 216
Study 3890786 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy plus BCG vaccine (24 patients)
Number of subjects: 216
Study 3890786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten-day chemotherapy (vincristine sulfate, cytarabine, prednisone)
Number of subjects: 216
Study 3890786 — intervention group
Group type: COMPARATOR
Intervention: Five-day chemotherapy (cytarabine)
Number of subjects: 216
Study 3890786 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival in evaluable patients with acute myelogenous leukemia
Number of subjects: 216
Study 30831300 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic transforaminal epidural injection (DTEI)
Number of subjects: 99
Study 30831300 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DTEI)
Number of subjects: 99
Study 30831300 — intervention group
Group type: EXPERIMENTAL
Intervention: DTEI
Number of subjects: 99
Study 29229342 — intervention group
Group type: EXPERIMENTAL
Intervention: Parahippocampectomy (PHC)
Number of subjects: 43
Study 29229342 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior temporal lobectomy (ATL)
Number of subjects: 43
Study 29229342 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective amygdalohippocampectomy (SAH)
Number of subjects: 43
Study 26956611 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g LNS/d
Number of subjects: 1932
Study 26956611 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g LNS/d
Number of subjects: 1932
Study 26956611 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g LNS/d
Number of subjects: 1932
Study 24481578 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneously implanted epidural ports (SIEP) with morphine administration (starting with 2 mg, maximum 4 mg per day)
Number of subjects: 21
Study 24481578 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneously implanted epidural ports (SIEP) with morphine administration
Number of subjects: 21
Study 22627883 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC)
Number of subjects: 10
Study 22627883 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa
Number of subjects: 10
Study 22627883 — intervention group
Group type: EXPERIMENTAL
Intervention: FEIBA
Number of subjects: 10
Study 22627883 — intervention group
Group type: EXPERIMENTAL
Intervention: PCC
Number of subjects: 10
Study 22627883 — intervention group
Group type: EXPERIMENTAL
Intervention: FEIBA (lower doses)
Number of subjects: 10
Study 20167582 — intervention group
Group type: EXPERIMENTAL
Intervention: win with the chin analogy
Number of subjects: 81
Study 20167582 — intervention group
Group type: EXPERIMENTAL
Intervention: anatomic instructions
Number of subjects: 81
Study 20167582 — intervention group
Group type: EXPERIMENTAL
Intervention: sniffing position analogy
Number of subjects: 81
Study 20167582 — intervention group
Group type: COMPARATOR
Intervention: no instructions (control)
Number of subjects: 81
Study 17056272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuban recombinant hepatitis B vaccine (Heberbiovac HB), 20 microg HBsAg/mL, administered in three doses at month 0, 1, and 2.
Number of subjects: 501
Study 17056272 — intervention group
Group type: COMPARATOR
Intervention: Control group (older production facilities).
Number of subjects: 501
Study 17134634 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy in white patients
Number of subjects: 1232
Study 17134634 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy in black patients
Number of subjects: 1232
Study 12565987 — intervention group
Group type: COMPARATOR
Intervention: 5-FU 60 mg/kg as a continuous infusion over 48 h, with methotrexate 40 mg/m(2) administered just before 5-FU (control regimen)
Number of subjects: 198
Study 12565987 — intervention group
Group type: EXPERIMENTAL
Intervention: PALA 250 mg/m(2) as a 15 min infusion administered 24 h before 5-FU and methotrexate
Number of subjects: 198
Study 12565987 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 198
Study 12565987 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm
Number of subjects: 198
Study 10926589 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling sessions (7 sessions over 3 months)
Number of subjects: 108
Study 10926589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counselling)
Number of subjects: 108
Study 8831323 — intervention group
Group type: EXPERIMENTAL
Intervention: One postoperative visit (Group A, n = 48)
Number of subjects: 144
Study 8831323 — intervention group
Group type: EXPERIMENTAL
Intervention: Two postoperative visits (Group B, n = 48)
Number of subjects: 144
Study 8831323 — intervention group
Group type: EXPERIMENTAL
Intervention: Three postoperative visits (Group C, n = 48)
Number of subjects: 144
Study 8831323 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 144
Study 1328817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (15 g/d for 4 weeks)
Number of subjects: 32
Study 1328817 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (15 g/d for 4 weeks)
Number of subjects: 32
Study 4062571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 8 gm twice daily, p.m. dose at different times
Number of subjects: 15
Study 4062571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 8 gm twice daily, p.m. dose 30 minutes before evening meal
Number of subjects: 15
Study 4062571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 8 gm twice daily, p.m. dose mid-afternoon
Number of subjects: 15
Study 4062571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 8 gm twice daily, all treatment periods
Number of subjects: 15
Study 30081930 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARC implementation intervention (EHR decision support, performance monitoring and feedback, front-line support from external practice coaches)
Number of subjects: 22
Study 30081930 — intervention group
Group type: COMPARATOR
Intervention: Pre-implementation period
Number of subjects: 22
Study 27780335 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 91
Study 27780335 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 91
Study 23588485 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered PNF hamstring stretching 2 × 40 seconds on each leg for 6 weeks
Number of subjects: 19
Study 23588485 — intervention group
Group type: COMPARATOR
Intervention: Static stretching 2 × 40 seconds on each leg for 6 weeks
Number of subjects: 19
Study 21743415 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin rinse (0.02%)
Number of subjects: 23
Study 21743415 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 23
Study 20464808 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy for pregnant substance users (MET‐PS)
Number of subjects: 200
Study 20464808 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 200
Study 20464808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 200
Study 17709169 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA testing and biopsy acceptance
Number of subjects: 58
Study 17709169 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA testing
Number of subjects: 58
Study 17709169 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders to PSA testing
Number of subjects: 58
Study 17709169 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy refusal
Number of subjects: 58
Study 17709169 — intervention group
Group type: EXPERIMENTAL
Intervention: General perceptions
Number of subjects: 58
Study 15986592 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided image analysis for microvessel density
Number of subjects: 50
Study 15986592 — intervention group
Group type: COMPARATOR
Intervention: Manual counting method for microvessel density
Number of subjects: 50
Study 15986592 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier curves for overall survival estimation
Number of subjects: 50
Study 11807436 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate strategy
Number of subjects: 0
Study 11807436 — intervention group
Group type: COMPARATOR
Intervention: Rotational strategy of modified cyclosporine and methotrexate
Number of subjects: 0
Study 10703890 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (verapamil 180 mg plus trandolapril 2 mg)
Number of subjects: 898
Study 10703890 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (dose-titration or switching to a different drug class)
Number of subjects: 898
Study 8732126 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuxuening tablet No. 1 (crude extract)
Number of subjects: 46
Study 8732126 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuxuening tablet No. 2 (pure extract)
Number of subjects: 46
Study 8732126 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuxuening tablet No. 1 and No. 2
Number of subjects: 46
Study 1748495 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms twice daily for 4 weeks
Number of subjects: 37
Study 1748495 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets twice daily for 4 weeks
Number of subjects: 37
Study 7140487 — intervention group
Group type: COMPARATOR
Intervention: Chenodeoxycholic (chenic) acid, 15 mg/kg/day, administered in three divided doses at mealtimes with an unrestricted diet (Group A)
Number of subjects: 48
Study 7140487 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime administration of chenodeoxycholic (chenic) acid, 15 mg/kg/day, with a low cholesterol diet (Group B)
Number of subjects: 48
Study 30228368 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic infiltration with 2.5 ml of 0.5% bupivacaine with 1:100000 epinephrine
Number of subjects: 23
Study 30228368 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 23
Study 28072552 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextenza (sustained-release dexamethasone intracanalicular insert)
Number of subjects: 59
Study 28072552 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (PV)
Number of subjects: 59
Study 24509880 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating-platform TKA
Number of subjects: 331
Study 24509880 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing TKA
Number of subjects: 331
Study 23306328 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg every other day)
Number of subjects: 39876
Study 23306328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39876
Study 21697538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit/Vegetable (FV)
Number of subjects: 101
Study 21697538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit/Vegetable/Berry (FVB)
Number of subjects: 101
Study 21697538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 19413207 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid malaria dipstick test (RDT)
Number of subjects: 515
Study 19413207 — intervention group
Group type: COMPARATOR
Intervention: Microscopy (Giemsa-stained thick and thin blood smears)
Number of subjects: 515
Study 16813177 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-picking therapy at bilateral Shengzhi points, Dicong Shenjing points and L2 Shenjing points
Number of subjects: 168
Study 16813177 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Wuzi Yanzong Pills
Number of subjects: 168
Study 12635531 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol (remifentanil 0.4 microgram/kg and propofol 1 mg/kg)
Number of subjects: 60
Study 12635531 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil-propofol (alfentanil 20 micrograms/kg and propofol 1 mg/kg)
Number of subjects: 60
Study 12635531 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol
Number of subjects: 60
Study 12635531 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil-propofol
Number of subjects: 60
Study 10720025 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (starting dose, 10 microg/kg x day, final dose 4 microg/kg x day)
Number of subjects: 40
Study 10720025 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 40
Study 10720025 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 40
Study 9161742 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms.kg‐1 i.v. before induction of anaesthesia
Number of subjects: 120
Study 9161742 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 120
Study 1547055 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 20
Study 1547055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3999921 — intervention group
Group type: EXPERIMENTAL
Intervention: Debrisoquin
Number of subjects: 10
Study 3999921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30014331 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline instillation (SI) 20-mL/kg of body weight
Number of subjects: 144
Study 30014331 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strategy of SI and pulmonary recruitment maneuver (RM)
Number of subjects: 144
Study 30014331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 144
Study 29579496 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing every four days
Number of subjects: 32
Study 29579496 — intervention group
Group type: COMPARATOR
Intervention: Bathing every two days
Number of subjects: 32
Study 26893320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailings of brochures
Number of subjects: 174
Study 26893320 — intervention group
Group type: EXPERIMENTAL
Intervention: Television advertisements
Number of subjects: 174
Study 26893320 — intervention group
Group type: EXPERIMENTAL
Intervention: Community events
Number of subjects: 174
Study 25635958 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 0.2 mL of monosodium glutamate (1.0 M) into the masseter muscle
Number of subjects: 16
Study 25635958 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 0.2 mL of monosodium glutamate (1.0 M) into the TMJ
Number of subjects: 16